Status: Not yet recruiting
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Participants needed: 425
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Fujian Shengdi Pharmaceutical Co., Ltd.Updated: Jun 26, 2026Locations: 2
Eligibility criteria
Male or female subjects, 18-75 years of age at the time of signing informed cons... [+3]
Presence of clinically significant lab or ECG results that may affect the evalua... [+16]